Literature DB >> 3300176

Multiple myeloma and polyclonal hypogammaglobulinaemia.

A Wangel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3300176     DOI： 10.1111/j.0954-6820.1987.tb01275.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN： 0001-6101


× No keyword cloud information.
  5 in total

Review 1.  Clinical Considerations for Immunoparesis in Multiple Myeloma.

Authors:  Michael Chahin; Zachery Branham; Ashley Fox; Christian Leurinda; Amany R Keruakous
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

2.  Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials.

Authors:  Jennifer L J Heaney; John P Campbell; Gulnaz Iqbal; David Cairns; Alex Richter; J Anthony Child; Walter Gregory; Graham Jackson; Martin Kaiser; Roger Owen; Faith Davies; Gareth Morgan; Janet Dunn; Mark T Drayson
Journal:  Leukemia       Date:  2018-06-20       Impact factor: 11.528

3.  Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma.

Authors:  Rajshekhar Chakraborty; Lisa Rybicki; Megan O Nakashima; Robert M Dean; Beth M Faiman; Christy J Samaras; Nathaniel Rosko; Hayley Dysert; Jason Valent; Faiz Anwer
Journal:  Br J Haematol       Date:  2020-02-28       Impact factor: 8.615

4.  Active multiple myeloma suppresses and typically eliminates coexisting MGUS.

Authors:  John P Campbell; Jennifer L J Heaney; Sankalp Pandya; Zaheer Afzal; Martin Kaiser; Roger Owen; J Anthony Child; Walter Gregory; Gareth J Morgan; Graham H Jackson; Chris M Bunce; Mark T Drayson
Journal:  Br J Cancer       Date:  2017-07-20       Impact factor: 7.640

5.  Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.

Authors:  Ilaria J Chicca; Jennifer L J Heaney; Gulnaz Iqbal; Janet A Dunn; Stella Bowcock; Guy Pratt; Kwee L Yong; Timothy D Planche; Alex Richter; Mark T Drayson
Journal:  Blood Cancer J       Date:  2020-11-04       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.